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Psoriasis is a common chronic
inflammatory disease with unpredictable
prognosis. Given the immunomodulatory effects of
statins, the present study was conducted to
determine whether the addition of orally
administered simvastatin to the topical
betamethasone, a standard antipsoriatic
treatment, can produce a more powerful
therapeutic response against this clinical
conundrum.
In a double-blind study, 30 patients with
plaque type psoriasis were randomly divided into
two equal treatment groups. Group 1 received oral
simvastatin (40 mg/d) plus topical steroid (50%
betamethasone in petrolatum) for 8 weeks and
group 2 received oral placebo plus the same topical
steroid for the same time period. Psoriasis Area and
Severity Index (PASI) score was checked before and
at the end of the treatment period.
PASI score decreased significantly in both
groups, but the decline of PASI score was more
significant in patients who received simvastatin
(Mann-Whitney test; P-value=0.001). No side effect
or any laboratory abnormality was detected in
patients.
Our work, which is the first double-
blind, randomized, placebo-controlled study on this
subject, shows that oral simvastatin enhances the
therapeutic effect of topical steroids against
psoriasis. The increased risk of cardiovascular
accidents in psoriatic patients and the protective
effect of statins against cardiovascular disease
further encourages their use in the treatment of this
clinical conundrum.
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Introduction
Psoriasis is a common chronic skin disease with
worldwide distribution. The prognosis is
unpredictable and recurrence is a rule regardless
of the type of treatment . Treatment modalities
are divided into local and systemic treatments,
including topical steroids, tar, anthralin, topical
retinoids, phototherapy, retinoids, methotrexate
and many other modalities, each associated with
many side effects .
Statins are well-known, safe and cheap
antihyperlipidemic drugs which inhibit 3-
Hydroxy-3-methyl glutaryl CoA (HMG-CoA)
reductase enzyme. In addition, they have proven
anti-inflammatory and immunomodulatory
effects via several mechanisms . Simvastatin
-2 4 decreases the
expression of adhesion molecules on monocytes
and macrophages , and inhibits leukocyte
function associated antigen-1 (LFA-1) .
The immunomodulatory effects of statins and
their potential use in the treatment of diverse
dermatological disorders were first introduced to
the dermatology literature in 2004 . Recently, a
non-randomized, non-controlled, open pilot
study on a small number of psoriatic patients (7
patients) revealed the reduction of PASI score
with orally administered simvastatin 40 mg/d
plus emollients or weak topical steroids for 8
weeks, suggesting the efficacy of statins against
psoriasis . Herein, we report the results of our
double-blind, randomized, placebo-controlled
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Patients and Methods
This study was conducted from November 2006 to
November 2007 at the Dermatology Department of
Shiraz University of Medical Sciences, the most
prestigious academic dermatology department of
the southern Iran. This study was approved by the
ethical committee of Shiraz University of Medical
Sciences.
Thirty otherwise-healthy patients with typical
psoriasis vulgaris who gave informed consent were
randomly divided into two equal groups.
The patients below 10 and above 80 years of age,
pregnant and lactating women, patients with
erythrodermic or pustular psoriasis, patients with
lesions on face and flexural areas, patients treated
with any topical or systemic medication in the past 1
month, and the patients with any hepatic or
muscular disorders were excluded from the study.
Patients in group 1 received simvastatin at the dose
of 20 mg two times daily plus topical steroid (50%
betamethasone in petrolatum) for 8 weeks.
Patients in group 2 received completely identical
oral placebo tablets twice daily plus the same
topical steroid for 8 weeks.
The severity of psoriasis was evaluated by a
physician blinded to treatment identifications
before the initiation of the treatment and after 8
weeks using Psoriasis Area and Severity Index (PASI)
score.
Serum levels of lactate dehydrogenase (LDH),
creatine phosphokinase (CPK) and also liver
function tests (LFT) were checked in all patients at
the beginning and at the end of the treatment.
The data were analyzed using Wilcoxon and
Mann-Whitney tests.
All 30 psoriatic patients (15 patients in each
group) completed the study. Group 1 (oral
simvastatin plus topical steroid) included 6 female
and 9 male patients. Group 2 (oral placebo plus
topical steroid) included 4 female and 11 male
patients. There was no significant difference
between sex ratios in the two groups (P=0.44).
The ages of the patients in group 1 were between
16 and 64 years (average: 38.5 years old) and in
group 2 were between 16 and 70 years (average:
45.4 years old). The difference in mean ages of the
two groups was not statistically significant (P=
0.27).
Results
In group 1, average baseline PASI score was 9.51,
which decreased to 3.38 after 8 weeks of
treatment (P-value = 0.001). In group 2, the
average baseline PASI seore was 5.64, which
decreased to 3.98 after 8 weeks of treatment (P-
value = 0.006). Mann-Whitney test revealed the
significantly more reduction of PASI score in group
1 compared to group 2 (P-value=0.001) (Table I).
No side effect or any laboratory abnormalities
were detected in any patient.
Table I: Average PASI score of psoriatic patients treated with oral simvastatin






Group 1* 9.51 3.83 0.001
Group 2 ** 5.64 3.98 0.006
PASI score reduction is more significant in group 1 than group 2 (Mann-Whitney test; P-value=0.001).
* Oral simvastatin plus topical betamethasone** Oral placebo plus topical betamethasone
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Discussion
Psoriasis is a relatively common recurrent Th1-
mediated chronic troublesome disease .
R e c e n t l y, t h e a n t i - i n f l a m m a t o r y a n d
immunomodulatory effects of statins have been
recognized and the results of treatment of some
autoimmune diseases, e.g. rheumatoid arthritis,
with these drugs have been encouraging .
The ability of statins to scavenge free radicals and to
modulate immune functions, as well as their low
cost and safety make them favorable candidates in
the treatment of immunologically-mediated
dermatologic diseases like psoriasis .
In the present study, oral simvastatin plus topical
steroid and oral placebo plus topical steroid were
both effective in the treatment of plaque type
psoriasis but the former treatment plan was more
effective than the latter.
Statins inhibit the expression of intercellular
adhesion molecule (ICAM-1), lymphocyte
function-associated antigen (LFA-1), and monocyte
chemotactic protein-1 (MAC-1) on leukocytes and
endothelial cells and interfere with LFA-1–ICAM-1
interaction through binding to LFA-1, thereby
suppressing leukocyte infiltration into the
inflammation site which is a hallmark of psoriasis
. Interference with LFA-1–ICAM-1 interaction and
i n h i b i t i o n o f e x p r e s s i o n o f m a j o r
histocompatability complex (MHC) class II results in
suppression of antigen presentation and
lymphocyte activation. Moreover, statins prevent
leukocyte entry to the inflammation sites by
significant downregulation of Th1-type chemokine
receptors, CCR5 and CXCR3, on T-cells and
inhibition of chemokine release by endothelial cells
.
Statins block the induction of inducible nitric oxide






proinflammatory cytokines, tumor necrosis factor-
α, interferon-γ, interleukin-8 (IL-8), IL-1β, and IL-6
in macrophages and induce a bias toward Th2
cytokines ex vivo .
2,3,11
Statins decrease C-reactive protein (CRP) serum
levels . CRP amplifies complement activation,
induces secretion of tissue factors from
monocytes, and enhances the expression of
adhesion molecules .
In the present study, simvastatin caused no
xerosis or eczema. Reiter et al have also shown
that simvastatin had no significant effect on the
skin cholesterol levels.
Activated inflammatory cells and pro-
inflammatory cytokines, which contribute to the
development of psoriatic lesions, play an
important role in the atherogenesis and the
breakdown of atherosclerotic plaques. Psoriasis is
associated with an increased cardiovascular risk
profile compared with the general population and
cardiovascular disease is an important cause of
morbidity and mortality in these patients. So,
statins can possess a double benefit for psoriatic
patients: improving their illness plus protecting
them against cardiovascular disease . Given the
different antipsoriatic mechanisms of retinoids
and statins, their co-administrations could prove
to exert a synergistic anti-psoriatic effect plus the
additional benefit of normalization of retinoid-
induced lipid abnormalities. There is some
evidence that statins exert anti-cancer effect ,
so administration of statins and phototherapy can
expedite the therapeutic response to
p h o t o t h e r a p y w h i l e m i t i g a t i n g t h e
carcinogenicity of the latter.
Noteworthy, a recent interesting paper by
Wolkenstein et al has shown the decreased risk
of psoriasis associated with statin intake.
Our work, which is the first double-blind,
randomized, placebo-controlled study on this
subject, reveals the marked beneficial effect of
adding statins (simvastatin 40 mg/d) to the topical
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